

PULMONARY HYPERTENSION AGENTS, ORAL AND INHALED

PRIOR AUTHORIZATION FORM (form effective 1/3/2022)

Prior authorization guidelines for **Pulmonary Hypertension Agents, Oral and Inhaled** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:		NPI:	State license #:	
LTC facility contact/phone:		Street address:		
Beneficiary name:		Suite #:	City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

CLINICAL INFORMATION

Drug name:	Strength:	Formulation:	
Dose/directions:		Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	
Has the beneficiary been taking the requested medication within the past 90 days?		<input type="checkbox"/> Yes <i>Submit documentation of drug regimen and clinical response.</i> <input type="checkbox"/> No	
Is the requested medication prescribed by or in consultation with a practitioner at a Pulmonary Hypertension Association-accredited center or other specialist skilled in treating pulmonary hypertension?		<input type="checkbox"/> Yes <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No	

INITIAL requests

For a non-preferred Pulmonary Hypertension Agent: Does the beneficiary have a history of trial and failure of or contraindication or intolerance to the preferred agents in this class that are approved or medically accepted for treatment of the beneficiary's condition? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred agents in this class.	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
--	--

Complete the sections below that are applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

- For treatment of PAH (WHO Group 1):**
- The requested medication is appropriate for the beneficiary's level of risk based on a current risk calculator assessment (e.g., REVEAL 2.0) and current medical literature
 - Had a right heart catheterization showing the following:
 - A mean pulmonary arterial pressure greater than 20 mmHg
 - A pulmonary capillary wedge pressure, left atrial pressure, or left ventricular end-diastolic pressure less than or equal to 15 mmHg
 - A pulmonary vascular resistance greater than or equal to 3 Wood units
 - Also, for idiopathic PAH:**
 - Has an H₂FPEF score less than 2
 - Has a left atrial volume index less than 35 mL/m²
 - Has a negative provocative test in a heart catheterization lab (fluid challenge with pulmonary capillary wedge pressure, left atrial pressure, or left ventricular end-diastolic pressure less than or equal to 17 mmHg)
 - Has chart documentation of acute vasoreactivity testing

- Has a medical reason for not having vasoreactivity testing
 - High risk stratification based on current risk calculator assessment (e.g., REVEAL 2.0)
 - Low systemic blood pressure
 - Low cardiac index
 - Pulmonary veno-occlusive disease
 - Other (*describe*): _____
- Demonstrates acute vasoreactivity
 - Has a history of trial and failure of or contraindication or intolerance to calcium channel blockers

For treatment of CTEPH:

- Has a mean pulmonary arterial pressure greater than 20 mmHg
- Has a pulmonary vascular resistance greater than or equal to 3 Wood units

RENEWAL requests

Does the beneficiary continue to benefit from the requested medication?	<input type="checkbox"/> Yes	<i>Submit documentation of clinical response.</i>
	<input type="checkbox"/> No	

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.